Post-earnings recap
Reported
Wed, Feb 25, 2026
EPS actual
$-1.86
EPS est.
$-1.56
EPS surprise
-19.00%
1-day move
-1.52%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that Revolution Medicines faced challenges, particularly reflected in their EPS miss. The stock reacted negatively, dropping 1.52%, likely due to the lack of revenue data and absence of guidance. Investors may be cautious as the company navigates its current environment and focuses on its pipeline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.86 | N/A | -19.00% |
| Revenue | N/A | N/A | N/A |
Management acknowledged the difficulties faced during the quarter. They emphasized their commitment to pipeline development, despite not providing specific guidance.
We are navigating a challenging environment.
Our focus remains on advancing our pipeline despite current setbacks.